Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

Rhea-AI Summary

Acurx Pharmaceuticals, a clinical stage biopharmaceutical company focused on innovative antibiotics, will have its President & CEO, David P. Luci, present at the Emerging Growth Conference on August 18, 2021, at 11:15 a.m. Eastern Time. This interactive online event aims to engage current stockholders and the investment community, allowing for potential Q&A. The conference will be webcast live and archived for 30 days on the company's website. Acurx is developing antibiotics targeting hard-to-treat infections, including MRSA and VRE.

STATEN ISLAND, N.Y., Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the Emerging Growth Conference as follows:

Date:	Wednesday, August 18, 2021
Time:	11:15 a.m. Eastern Time
Webcast:	https://goto.webcasts.com/starthere.jsp?ei=1486517&tp_key=3bd9735fe4&sti=acxp

This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci.  As time permits, Mr. Luci may be able to respond to questions from participants.

The presentations will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company's website at www.acurxpharmaceuticals.com, under the Investors section.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D preclinical pipeline includes antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).   

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com. 

Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel:  917-533-1469
Email:  davidluci@acurxpharma.com

View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-august-18-2021-301353864.html

SOURCE Acurx Pharmaceuticals, Inc.

FAQ

What is the date of Acurx Pharmaceuticals' presentation at the Emerging Growth Conference?

Acurx Pharmaceuticals will present at the Emerging Growth Conference on August 18, 2021.

What time will Acurx Pharmaceuticals present at the Emerging Growth Conference?

Acurx Pharmaceuticals' presentation is scheduled for 11:15 a.m. Eastern Time on August 18, 2021.

Where can I watch Acurx Pharmaceuticals' presentation?

Acurx Pharmaceuticals' presentation will be webcast live at their website and archived for 30 days.

Who is the CEO of Acurx Pharmaceuticals?

The CEO of Acurx Pharmaceuticals is David P. Luci.

What is the focus of Acurx Pharmaceuticals?

Acurx Pharmaceuticals focuses on developing a new class of antibiotics for difficult-to-treat bacterial infections.

What types of infections is Acurx Pharmaceuticals targeting with its antibiotics?

Acurx Pharmaceuticals is targeting infections such as those caused by MRSA and VRE.

What is the stock symbol for Acurx Pharmaceuticals?

The stock symbol for Acurx Pharmaceuticals is ACXP.